复方多黏菌素B软膏联合重组人表皮生长因子治疗糖尿病皮肤难愈性溃疡的效果分析  

Analysis of the Effect of Compound Polymyxin B Ointment combined with Recombinant Human Epidermal Growth Factor in the Treatment of Diabetic Skin Ulcers

作　　者：闫晓航 YAN Xiaohang(Department of Burns,Changchun Central Hospital,Changchun,Jilin Province,130021 China)

机构地区：[1]长春市中心医院烧伤科,吉林长春130021

出　　处：《糖尿病新世界》2022年第1期1-4,共4页Diabetes New World Magazine

摘　　要：目的对糖尿病皮肤难愈性溃疡患者使用复方多黏菌素B软膏联合重组人表皮生长因子治疗的临床效果进行探析。方法将2018年2月—2020年2月该院治疗的78例糖尿病皮肤难愈性溃疡患者列为研究对象,根据随机数表法将患者随机分成常规组和观察组,各39例,创面深度均为深二度。常规组患者使用复方多黏菌素B软膏进行治疗,观察组使用复方多黏菌素B软膏结合重组人表皮生长因子进行治疗。将两组患者治疗情况(临床指标、溃烂愈合情况、治疗有效率)进行分析比较。结果观察组治疗有效率为97.44%,显著高于常规组,差异有统计学意义(χ^(2)=7.341,P=0.007);观察组溃烂面积、生活质量评分、空腹血糖、餐后2 h血糖水平、溃疡愈合速率、平均祛腐时间、平均生肌时间、平均愈合时间、换药次数分别为(3.54±1.76)cm^(2)、(82.98±10.62)分、(4.25±0.73)mmol/L、(5.36±1.62)mmol/L、(60.13±2.14)%、(13.84±4.80)d、(15.15±7.03)d、(26.66±7.28)d、(18.82±3.80)次,显著优于常规组,差异有统计学意义(t=8.830、8.138、10.706、8.246、82.288、8.462、10.623、8.307、8.693,P<0.001)。结论为糖尿病皮肤难愈性溃疡患者使用复方多黏菌素B软膏联合重组人表皮生长因子进行治疗,可以改善患者血糖水平,且可以提升患者生活质量,患者溃疡愈合状况良好,临床应用价值较高。Objective To investigate the clinical effect of using compound polymyxin B ointment combined with recombinant human epidermal growth factor in patients with diabetic skin ulcers that are difficult to heal. Methods A total of 78 patients with refractory diabetic skin ulcer treated in this hospital from February 2018 to February 2020 were included as the research objects. According to the random number table method, the patients were randomly divided into the conventional group and the observation group, with 39 cases in each group, and the wound depth was 2 degrees. Patients in the conventional group were treated with compound polymyxins B ointment, and patients in the observation group were treated with compound polymyxins B ointment combined with recombinant human epidermal growth factor. The treatment of the two groups of patients(clinical indicators, ulceration, treatment efficiency) were analyzed and compared. Results The effective rate of observation group was 97.44%, significantly higher than that of conventional group, the difference was statistically significant(χ^(2)=7.341, P=0.007). Ulcerated area,quality of life score, fasting blood glucose, postprandial 2 h blood glucose level, ulcer healing rate, mean muscle growth time, mean decomposition time, mean healing time and dressing change times were(3.54±1.76) cm^(2),(82.98±10.62) points,(4.25±0.73) mmol/L,(5.36±1.62) mmol/L,(60.13 ±2.14) %,(13.84±4.80) d,(15.15±7.03) d,(26.66 ±7.28) d,(18.82 ±3.80) times, significantly better than the conventional group, the difference was statistically significant(t=8.830, 8.138, 10.706, 8.246, 82.288, 8.462, 10.623, 8.308, 8.694, P<0.001). Conclusion The use of compound polymyxin B ointment combined with recombinant human epidermal growth factor for the treatment of diabetic skin ulcers can improve the blood glucose level of the patients. And it can improve the quality of life of patients, the ulcer healing of patients is in good condition, and the clinical application value is high.

关 键 词：复方多黏菌素B软膏 重组人表皮生长因子 糖尿病 皮肤难愈性溃疡 愈合疗效 

分 类 号：R59[医药卫生—内科学]